Across TCGA pan-cancer cohorts, KRT6A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRT6A data layer compared with 17 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KRT6A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KRT6A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where KRT6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.409	0.873	.007	30	view →
HNSC	DFS	Tertile	All	1.000	0.906	.007	14	view →
LUAD	DFS	Tertile	II,III,IV	0.261	0.786	.006	7	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.792	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRT6A tumor-vs-normal RNA expression · all KRT6A data types